Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024


AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.


These press releases may also interest you

at 14:20
Gastroesophageal Reflux Disease (GERD) Market size is set to grow by USD 879.8 million from 2024-2028, Rising geriatric population to boost the market growth, Technavio
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransContm PTH in Canada
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
IMPERIAL TOBACCO CANADA ADVOCATES FOR A NEW FEDERAL FRAMEWORK THAT TREATS ALL NICOTINE REPLACEMENT THERAPIES (NRTs) EQUALLY
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
Global Regenerative Medicine Partnering Deals Analysis Report and Directory 2016-2024: 1771 Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
Diagnostic Imaging Partnering Analysis Report and Directory 2016-2024: 628 Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

More news about Health...


News published on and distributed by: